179 related articles for article (PubMed ID: 28590314)
1. Novel imaging in advanced prostate cancer.
Goldberg H; Hamilton RJ
Curr Opin Support Palliat Care; 2017 Sep; 11(3):238-246. PubMed ID: 28590314
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer PET tracers: essentials for the urologist.
Fraum TJ; Ludwig DR; Kim EH; Schroeder P; Hope TA; Ippolito JE
Can J Urol; 2018 Aug; 25(4):9371-9383. PubMed ID: 30125515
[TBL] [Abstract][Full Text] [Related]
3. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
6. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
7. New Targets for PET Molecular Imaging of Prostate Cancer.
Mena E; Lindenberg LM; Choyke PL
Semin Nucl Med; 2019 Jul; 49(4):326-336. PubMed ID: 31227055
[TBL] [Abstract][Full Text] [Related]
8. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
9. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
[TBL] [Abstract][Full Text] [Related]
10. Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.
Meyer AR; Joice GA; Allaf ME; Rowe SP; Gorin MA
Curr Opin Urol; 2018 Nov; 28(6):493-498. PubMed ID: 30188333
[TBL] [Abstract][Full Text] [Related]
11. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
[TBL] [Abstract][Full Text] [Related]
12. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
13. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
14. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
15. The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.
Rai BP; Baum RP; Patel A; Hughes R; Alonzi R; Lane T; Adshead J; Vasdev N
Urology; 2016 Sep; 95():11-5. PubMed ID: 26790588
[TBL] [Abstract][Full Text] [Related]
16. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
17. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
18. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Imaging with Novel PET Tracers.
Lindenberg L; Choyke P; Dahut W
Curr Urol Rep; 2016 Mar; 17(3):18. PubMed ID: 26874530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]